Pregabalin vs Placebo in Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00143156|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : April 14, 2008
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Neuropathies||Drug: pregabalin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||450 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With Diabetic Peripheral Neuropathy|
|Study Start Date :||March 2005|
|Actual Study Completion Date :||May 2007|
- The primary efficacy parameter is the endpoint End of Week 12 weekly mean pain score derived from the pain diary.
- End of Week 12 responder rates, Brief Pain Inventory - short form, sleep interference scores, Medical Outcome Study - Sleep Scale, Hospital Anxiety and Depression Scale, Patient Global Impression of Change, Neuropathic Pain Inventory Symptom Inventory.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143156
Show 55 Study Locations
|Study Director:||Pfizer CT.gov Call Center||Pfizer|